Allergy medicine may help ‘reinvigorate’ immunotherapy to treat lung cancer

A preclinical study conducted at the Icahn School of Medicine at Mount Sinai has found an allergy pathway that, when blocked, triggers antitumor immunity in mouse models of non-small cell lung cancer.
Moreover, an early parallel study in humans demonstrated similar findings with a combination of immunotherapy and dupilumab, yielding significant tumor reduction in one out of six patients treated.
“The reasons patients respond to immune therapy and then stop eventually are very different from one patient to the other,” study co-senior author Thomas U. Marron, MD, PhD, director of the

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart